Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

How long should we treat?

(2014) C. Roux et al.   OSTEOPOROSIS INTERNATIONAL

Global Consensus Statement on Menopausal Hormone Therapy

(2013) T. J. de Villiers et al.   CLIMACTERIC

Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials

(2013) JoAnn E. Manson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

(2012) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

(2012) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy

(2011) Andrea Z. LaCroix   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM